Abstract
Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy with a high relapse rate. In recent years, immunotherapy has achieved certain curative effects in AML. A considerable proportion of AML patients can achieve long-term survival after allogeneic hematopoietic stem cell transplantation, adoptive immunotherapy, monoclonal antibody and vaccine therapy. But immunotherapy still can not meet the needs of all AML patients. Immunotherapy of AML has great potential for development, and it is expected that various immune therapies can better improve the efficacy of AML in the case of giving full play to their advantages and reducing side effects. Key words: Leukemia, myeloid, acute; Immunotherapy
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
